Table 1.
Patient and tumor characteristics
| Characteristic | n | % | |
|---|---|---|---|
| All patients | 277 | ||
| Age (years) | |||
| Median | 67 | ||
| Range | 47-81 | ||
| Gleason score | |||
| ≤ 6 | 179 | 64.6 | |
| 7 | 91 | 32.9 | |
| 8 | 7 | 2.5 | |
| iPSA (ng/ml) | |||
| Median | 7.85 | ||
| Range | 1.8-59.5 | ||
| T stage (DRE or image- based) | |||
| T1c | 217 | 78.3 | |
| T2a | 54 | 19.5 | |
| T2b | 3 | 1.1 | |
| T2c | 3 | 1.1 | |
| NADT | |||
| Yes | 94 | 33.9 | |
| No | 183 | 66.1 | |
| Risk group | |||
| Low | 145 | 52 | |
| Intermediate | 116 | 42 | |
| High | 16 | 6 | |
| Positive biopsy cores (%) | |||
| Median | 30 | ||
| Range | 5-100 | ||
| HDR-BT dose | |||
| 19-20 Gy/1 fraction | 87 | 31.4 | |
| 27 Gy/2 fractions | 41 | 14.8 | |
| 38 Gy/4 fractions | 149 | 53.8 | |
| Adjuvant ADT | |||
| Yes | 6 | 2.2 | |
| No | 271 | 97.8 | |
NADT – neoadjuvant androgen deprivation therapy, ADT – androgen deprivation therapy, DRE – digital rectal examination, iPSA – initial prostate-specific antigen, HDR-BT – high-dose-rate brachytherapy